Alnylam Pharmaceuticals
Cambridge
About Alnylam Pharmaceuticals
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $1M – $10M
- Total funding: $4.5B
- Funding stage: IPO
- Last round: Post-IPO Debt (Sep 2025)
- Ticker: nasdaq:ALNY
- Website: alnylam.com
- Phone: 617.551.8200
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/alnylam-pharmaceuticals-23673 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.